The U.S. FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel on March 25, 2026, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received 1-3 prior systemic treatments including bevacizumab.124
Approval came 2.5-3 months ahead of schedule.123
Based on ROSELLA trial (381 patients):
combination therapy reduced death risk by 35% (median OS 16.0 vs. 11.9 months) and progression risk by 30% (PFS 6 vs. 5.5 months).123
Corcept shares surged 21-32% post-approval.13
Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist.1
Dosing:
150 mg oral relacorilant daily for 3 days around nab-paclitaxel (80 mg/m² IV on days 1,8,15 of 28-day cycle).2
Warnings include neutropenia, infections, adrenal insufficiency, embryo-fetal toxicity; common AEs:
low hemoglobin/neutrophils/platelets, fatigue, nausea, diarrhea, rash, low appetite.12
Sources:
1. https://www.investing.com/news/company-news/fda-approves-corcepts-lifyorli-for-ovarian-cancer-treatment-93CH-4580520
2. https://www.streetinsider.com/Corporate+News/FDA+approves+Corcepts+relacorilant+combination+for+platinum-resistant+ovarian+cancer/26214942.html
3. https://economictimes.indiatimes.com/markets/us-stocks/news/corcept-therapeutics-shares-surge-32-as-lead-drug-gets-fda-nod-for-ovarian-cancer/articleshow/129806851.cms
4. https://www.tipranks.com/news/company-announcements/corcept-wins-fda-approval-for-lifyorli-ovarian-cancer-therapy